Enrolling Studies

Read Our Testimonials

Enrolling Trials

Clinical trials are at the heart of medical advances. Clinical trial participants enroll to possibly receive the latest treatments for their condition, to receive additional care and attention from our professional staff, and to help find better treatments for future patients. In the United States, clinical trials must meet rigorous standards and be registered and approved by regulatory agencies. Participation is free of charge and transportation can be provided for all trial participants. To learn if you are eligible to participate in our enrolling studies, please contact us at:

Call us at 512-279-1251

Email: Ivana Gunderson

About 10-20% of macular degeneration is classified as the wet form. In this form, there is often a rapid onset of distortion and blurring of the vision in one eye due to leakage or bleeding in the macula. If diagnosed early, currently available drugs are quite effective in maintaining or improving vision when injected into the eye. These treatments are not a cure and must be continued indefinitely to maintain vision. When one eye progresses to the wet form of the disease there is an increased risk of about 10% annually for the other to develop the same condition.  Current research is aimed at reducing the number of treatments and improving vision.

  • Regenexbio RGX-314-2104 Atmosphere -A Phase 2b/3 study evaluating efficacy of a single administration of RGX-314 gene therapy compared to standard of care Lucentis injections in patients with wet AMD.
  • Eyepoint EYP-1901 Lucia – A phase 3 study comparing the efficacy of EYP-1901 against Aflibercept in patients with wet AMD.
  • Roche Burgundy – A study evaluating continuous delivery of a new drug delivered through an implanted device, port delivery system (PDS), compared to FDA approved Lucentis delivered via the PDS.  
  • 4DMT 4D-150-C003 4Front-1 – A Phase 3 study evaluating efficacy of a single administration of 4D-150 gene therapy compared to standard of care Eylea injections in patients with wet AMD.
  • Alcon RTE888-E001 Nova-1 – A Phase 2 study comparing the efficacy of AR-14034 SR against Aflibercept in patients with wet AMD.

Diabetic retinopathy is the leading cause of vision loss in working age Americans. It is a common cause of permanent visual impairment in middle age and is a complication of diabetes. The risk of developing diabetic retinopathy is related to length of diabetes and poor diabetic control. It can be asymptomatic and is most commonly found on a routine retinal exam. Diabetes damages the fragile blood vessels in the retina leading to hemorrhages and leakage. Current treatments can reduce the blood vessel damage when the drugs are injected into the eye. Current research is directed at developing longer lasting drugs and treatments that can decrease the severity of diabetic retinopathy to prevent significant complications.

  • Boehringer-Ingelheim 1436-0007 Crimson – A Phase 2 study evaluating 3 different doses of a new drug administered with an eye injection in patients with non-proliferative diabetic retinopathy

Diabetic patients can have chronic leakage of blood vessels that can lead to diabetic macular edema, or swelling of the retina. This is the leading cause of vision loss from diabetic retinopathy. It causes a progressive blurring of the vision that is not correctable with glasses. This can be successfully treated with current drugs about 60% of the time. Current drugs are injected into the eye on a monthly basis as needed. It is commonly in both eyes, but may not affect both eyes at the same time. Current research is directed at developing more effective and longer lasting treatments.

  • Genentech BP44175 Pregonda (Part 2)– A phase 1 study evaluating the safety of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.
  • Genentech GR43828 THAMES– A phase I/II study to evaluate the efficacy of RO7446603 administered alone or in combination with Aflibercept or Faricimab in patients with diabetic macular edema.
  • Kyowa Kirin 4951-003– A Phase 2 study assessing KHK4951 eye drops in combination with FDA approved Eylea in patients with diabetic macular edema.

Macular degeneration is the leading cause of irreversible vision loss in elderly Americans. It is more common in people of northern European ancestry, it tends to run in families, and it is a progressive condition associated with aging. The macula is the central specialized area of the retina associated with color vision and reading. Macular degeneration does not affect peripheral vision and does not lead to total loss of vision. In its advanced forms, it can make it difficult to read and impossible to drive. It always affects both eyes and there is no cure.

Most macular degeneration is classified as the dry form. This label means that there is no associated bleeding or leakage in the macula. In the advanced stages, areas of atrophy, called geographic atrophy (GA) form resulting in missing spots in vision. Current research is focused on slowing or stopping the progression of geographic atrophy and vision loss.

  • Boehringer Ingelheim 1497-0002 VERDANT– A Phase 2 study evaluating a new drug compared to an FDA approved treatment in patients with geographic atrophy due to dry AMD
  • Boehringer Ingelheim 1484-0005 JADE– A Phase 2 study evaluating a new drug compared to a placebo in patients with geographic atrophy due to dry AMD
  • Genentech GR44251 GAlette– A Phase 2 study evaluating the subretinal surgical delivery of stem cells in participants with geographic atrophy due to dry AMD
  • Roche BP45482– A Phase 1 study evaluating a new drug compared to FDA approved treatments (Syfovre & Izervay) in patients with geographic atrophy due to dry AMD

Macular telangiectasia type 2 is a rare congenital retinal disease that usually manifests itself in young adults or middle age. It can lead to blurred vision in one or both eyes. There is currently no FDA approved treatment for this condition. We are enrolling patients in a nationwide registry study that will help gather data on this rare condition that may help with future clinical trials and development of treatments. Participating in the registry consists of a one-time in office visit that is of no cost to the patient and benefits include: confirmation of diagnosis by an independent central reader, and to stay informed about future interventional clinical trials.

  • Mactel NHOR– A natural history, observation, and registry study of macular telangiectasia type 2.

Retinal vein occlusions are the third most common retinal disease leading to loss of vision. They are associated with aging of the blood vessels. This can be exacerbated by hypertension and diabetes. Glaucoma is also a risk factor. Current treatments are successful in improving vision about 75% of the time. The treatments include drugs that are injected into the eye and laser surgery. Current research is directed at developing more effective and longer lasting drugs.

  • We have an exciting new study evaluating a novel treatment pathway for patients newly diagnosed with a central retinal vein occlusion. Please contact our office to learn more, and see if you might be a good candidate for this study.
  • No enrolling trials at this time

  • No enrolling trials at this time
  • No enrolling trials at this time
  • No enrolling trials at this time

Closed Trials

Below is a list of trials investigators and staff have participated in. The data has been analyzed by the pharmaceutical companies sponsoring the trials, and those companies have moved the drugs to the next stage of development for the particular medication in question, have submitted for FDA approval, or did not pursue the development of that particular treatment.

9707 Anderson Mill Road,
Suite 100
Austin, TX 78750
Phone:
512-279-1251
Fax:
512-600-2882
©2025. All Rights Reserved.
Designed by Glacial Multimedia
If you are using a screen reader and are having problems using this website, please call 512-279-1251.
Accessibility Disclaimer
Privacy Policy

Contact Us

WARNING: Internet Explorer does not support modern web standards. This site may not function correctly on this browser and is best viewed on Chrome, Firefox or Edge browsers. Learn More.